Home > Dermatology > EADV 2019 > Late-Breaking News > Topical ruxolitinib effective in vitiligo

Topical ruxolitinib effective in vitiligo

Presented By
Prof. Amit Pandya, University of Texas Southwestern Medical Center, USA
EADV 2019
Vitiligo pathogenesis is driven by signalling through Janus kinase (JAK) 1 and 2. In a clinical trial, topical ruxolitinib cream produced substantial facial and total body repigmentation up to 1 year [1]. Vitiligo is a chronic autoimmune disease of the skin that targets melanocytes, resulting in patches of skin depigmentation [2]. Expression of interferon (IFN)-γ is increased in the lesional skin of patients. Neutralisation of IFN-γ prevents CD8(+) T-cell accumulation and depigmentation, suggesting a therapeutic potential for this approach [3]. Thus, JAK1/JAK2 inhibitors appear effective in vitiligo, presumably via inhibition of IFN-γ signalling in the skin [4]. Ruxolitinib cream across a dose range of 0.15 to 1.5% provided significant repigmentation of facial vitiligo lesion after 24 weeks of double-blind, vehicle-controlled treatment [5]. After the blinded study phase, all patients were re-randomised and then treated with 1.5% ruxolitinib cream fo...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on